Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML)

The objective of this study is to demonstrate that cytokine-induced memory-like natural killer cells can be generated from donor cells and infused safely into patients with relapsed or refractory acute myeloid leukemia (AML). A secondary objective is to assess efficacy of the CIML-NK cells in treating AML.

Trial Details

NCT ID
NCT05580601
Phase
PHASE1 / PHASE2
Sponsor
Children's Hospital Medical Center, Cincinnati
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • CIML-NK Cells
Locations (sample)
  • Cincinnati, Ohio, United States|39.12711,-84.51439

Key Eligibility Criteria

  • Of age ≥ 2 years of age at the time of study enrollment
  • With AML diagnosed per 2016 WHO criteria (11)
  • With relapsed or refractory AML in their bone marrow
  • Refractory disease: Patients must have ≥ 5% blasts in the bone marrow after 2 courses of intensive induction treatment

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →